All Genomics & Sequencing articles
-
NewsParse Biosciences and bit.bio map transcription factor-driven cell identity
Parse Biosciences and bit.bio have formed an alliance to map transcription factor-driven cell identity using single cell sequencing and causal transcriptomics.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
ArticleTurning GWAS signals into drug targets with scalable CRISPR
Genome-wide association studies have linked thousands of genetic variants to disease, yet most remain disconnected from drug-relevant biology. Neville Sanjana, Professor at New York University and Core Faculty Member at the New York Genome Center, explains how scalable CRISPR screens systematically link noncoding variants to causal genes and therapeutic targets.
-
NewsOutSee wins Longitude Prize award for ALS target discovery
OutSee has secured a Discovery Award from the Longitude Prize on ALS, providing £100,000 in funding and access to genomic data from 9,000 patients. The company will deploy its AI-driven Nomaly platform to identify novel therapeutic targets for amyotrophic lateral sclerosis over a nine-month research programme.
-
NewsAI-designed viral vectors achieve 50-fold brain enrichment over AAV9
WhiteLab Genomics has presented preclinical data showing that viral vectors designed using artificial intelligence achieved approximately 50-fold higher DNA enrichment in the brain compared to AAV9, with no detectable liver signal following intravenous administration in mice.
-
NewsNew RNA sequencing method reveals molecular structures at single-molecule resolution
A*STAR scientists have developed sm-PORE-cupine, a nanopore-based sequencing method that maps individual RNA structures at single-molecule resolution.
-
NewsASGCT 2026 Annual Meeting opens in Boston this week
The American Society of Gene & Cell Therapy’s 2026 Annual Meeting opens in Boston on 11 May, bringing together thousands of researchers, clinicians and industry leaders for five days of scientific programming.
-
ArticleTurning CRISPR hits into confident drug discovery decisions
Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman Tamaddon-Jahromi, a postdoctoral research associate at the University of Cambridge, discusses how end-to-end CRISPR screening strategies, iPSC-derived neuronal models and layered quality control can convert functional genomics signals into actionable therapeutic hypotheses.
-
ArticleThe scale divide: competing strategies in AI drug discovery
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
-
NewsAI tool reveals DNA exists in partially open states
Researchers have discovered that DNA wrapped around nucleosomes exists in multiple partially open states rather than simply locked or accessible configurations.
-
NewsNew immune mapping reveals lung tumour microenvironment dynamics
VIB-VUB researchers have developed a patient-relevant lung adenocarcinoma model combined with SEPARATE-Seq technology to create detailed immune maps distinguishing tissue-infiltrating cells from circulating populations.
-
ArticleVariant or viable target? How resolving complex genomic regions is reshaping rare disease therapeutics
Dr Aaron Wenger reveals how improvements in long-read sequencing technology is enabling the elucidation of complex disease mechanisms for targeted and effective treatments for rare diseases.
-
News10x Genomics launches Atera whole-transcriptome spatial biology platform
The new platform enables researchers to analyse gene expression and cellular organisation within intact tissue at single-cell resolution, supporting large-scale studies across fresh-frozen and FFPE samples. Early adopters include leading research institutions and global service providers, with cloud-based analysis tools and direct sample processing services now available.
-
NewsNew platform reveals shared drug targets across genetic mutations in cancer and neurodegeneration
Researchers have developed PerturbFate, a platform that simultaneously tracks gene expression, RNA dynamics and chromatin accessibility across thousands of genetic perturbations in single cells. Applied to melanoma drug resistance, the technology revealed that diverse mutations converge on shared regulatory nodes, offering a route to therapies targeting common mechanisms rather than individual genetic alterations.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsOsteoporosis drugs may slow progression of aortic aneurysms
Researchers at Nagoya University have identified clonal haematopoiesis as a driver of aortic aneurysm progression and demonstrated that FDA-approved osteoporosis therapies targeting the RANK/RANKL pathway can significantly slow disease progression in preclinical models.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
InterviewComputational design drives new generation of synthetic promoters
Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.
-
NewsScientists link IVNS1ABP gene to new ageing disorder
An international research team has identified a previously unknown genetic disease characterised by premature ageing and progressive neurological decline. Using genome sequencing combined with induced pluripotent stem cell technology, scientists traced the condition to a mutation in the IVNS1ABP gene and uncovered disrupted actin dynamics during cell division as the underlying pathological mechanism.
-
InterviewFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.